Name: targeting cysteine thiols for in vitro site-specific glycosylation of recombinant proteins
Uploaded: 2017-10-04T12:00:00.000+00:00
Duration: 11 min 25 s
Description: Watch this Scientific Journal Video about Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins at JoVE.com

这项研究得到了加拿大自然科学和工程研究理事会 (05239 至 P.B.S.)、加拿大创新基金会/安大略省研究基金 (P.B.S.)、前列腺癌防治基金会--科学爸爸 (P.B.S.) 和安大略的支持。研究生奖学金 (Y.J.C. 和生理盐水)。

1. 聚合酶链反应 (PCR) 介导的定点诱变, 将胱氨酸纳入细菌 pET-28a 表达载体. 
<ol> <li> 使用 0.020 (#956; g/毫升) cm -1 在 260 nm 的紫外线 (UV) 消光系数确定 pET-28a 向量 (即双绞链 DNA) 的浓度. </li>
	<li> 为每个胱氨酸突变合成一对互补诱变底漆, 这样 i ) 在第一个基不匹配和15核苷酸与模板互补之后, 至少有15核苷酸与模板互补。最终基不匹配, ii ) 总引物长度不超过45核苷酸, 和 iii ) 鸟嘌呤或胞嘧啶位于每个底漆的第一和最后一个核苷酸位置 (表 1)。确保使用0.025 和 #956 进行底漆合成; 摩尔刻度和墨盒净化. </li>
	<li> 使用高保真 DNA 聚合酶, 建立两个20和 #181; PCR 反应混合物: 一个包含前引物和第二个包含反向底漆。准备每个混合物, 以包含最终浓度的1x 和 #160;P cr 缓冲器 1.5 mM 氯化镁 2 , 0.2 毫米 dNTPs, 0.5 和 #956; M 型底漆, 0.4 和 #956; l 甲基亚砜, 1.25 ng/和 #956; l 模板 dna, 0.02 U/和 #956; 高保真 dna 聚合酶. </li>
	<li> 使用三步协议热循环分离的混合物:98 和 #176; c 为三十年代 (变性), 53-56 和 #176; c 为三十年代 (退火), 72 和 #176; c 为三十年代 kilobase (kb) -1 (扩展) 模板脱氧核糖核酸。重复5周期的温度程序, 并添加最后72和 #176; C 扩展步骤为 7.5 min. </li>
	<li> 在最初的 pcr 与前向和反向引物在分开的管子, 结合产品成一个单独管子 (即40和 #956; L 共计) 和继续 pcr 反应为另外20个周期使用相同的循环参数, 如步骤1.4 所述. </li>
	<li> Electrophorese 15 和 #956; PCR 反应混合物的 L 在 1% (w/v) 琼脂糖凝胶使用0.5x 三, 乙酸, 乙二胺四乙酸 (EDTA) 运行缓冲器 (泰)。作为控制, electrophorese 了一个相当数量的模板 dna 没有被放大的 pcr 和分的参考 dna 阶梯, 其中包含标记带比预期的 pcr 产品大小. </li>
	<li> 在120伏电泳40分钟后, 将凝胶浸入含有0.5 和 #956 的水中; 在室温下, 溴溴化物并摇动30分钟。确认的全长模板已被放大的诱变底漆作为增加相对溴溴荧光强度的放大带相比, 控制模板带在紫外线 (302 nm)。
	<ol> <li> 如果没有明显的放大, 则在0.5 和 #176 中调整退火温度后重复 PCR; c 在 53-56 和 #176 之间递增; c 温度范围. </li>
	</ol> </li> <li> 通过诱变底漆确认模板的放大后, 将剩余的 ~ 25 和 #956; PCR 反应混合物与 DpnI 限制性酶结合, 以消化甲基化模板 DNA。使用 DpnI 0.5 和 #181; l (10 单位) 每25和 #956; PCR 反应混合物和最终浓度1和 #215; DpnI 反应缓冲器。在37和 #176 孵育2.5 小时; C. </li>
	<li> 以下模板消化, 添加〜 5-10 和 #956; 消化混合物的 l 100 和 #181; 热休克主管 DH5 和 #945; 大肠杆菌大肠杆菌 1.75 毫升离心管中的细胞。在冰上孵育细胞 DNA 混合物60分钟. </li>
	<li> 热休克离心管的细胞 DNA 混合物在42和 #176; C 四十五年代在干燥热块。在冰上孵育3分钟的混合物后, 加入900和 #956; 室温 Luria Bertani 肉汤 (LB) 至细胞, 并将总细胞悬浮液转化为无菌14毫升圆底管. </li>
	<li> 孵育37和 #176 的细胞悬浮液; C 为90分钟, 在 190 rpm 时持续晃动. </li>
	<li> 随后, 将电池悬浮液转换回1.75 毫升离心管, 并在室温下 1万 x g 离心5分钟. </li>
	<li> 离心后, 取出900和 #956; 在其余100和 #956 中, 用温和的移重细菌细胞; l。
	<li> 将合成的浓缩细胞悬浮液转移到含有抗生素的 LB 琼脂板上, 这是选择性的表达载体 (即60和 #956; g/mLKanamycin)。菌将悬浮液均匀地涂在琼脂板上, 在37和 #176 上孵育16小时; C. </li>
	<li> 第二天, 将单个菌落从板材接种到5毫升的液体 LB 中, 其中含有 antiobiotic 选择压力 (即60和 #956;在37和 #176 的夜间培养液体培养基; c. 在37和 #176 时持续晃动; c. </li>
	<li> 将传播质粒从 大肠杆菌中分离和纯化 使用基于碱性裂解过程的商用套件的细胞 45 。
	<li> 确认感兴趣的突变是存在的, 并在适当的阅读框架中, 通过桑格 DNA 测序的质粒 46 . </li>
</ol> 2。BL21 和 #916 中的均匀 15 N 标记蛋白表达; E3 大肠杆菌 . 
 注意: 不同的重组蛋白需要不同的表达条件。以下是人类 STIM1 EFSAM 蛋白表达的优化过程. 
<ol> <li> 将胱氨酸突变 (即 pET-28a-EFSAM) 的表达载体转换为 BL21 和 #916; E3 密码子 (+) 热休克主管细胞和板上的 LB 琼脂板包含抗生素选择压力, 如步骤 1.9-1.14) 与以下修改: 直接板150和 #956; l 分出1000和 #956; l 在 LB 琼脂板上的总细胞悬浮, 不需要用离心法将离心管中的细胞浓缩. </li>
	<li> 第二天, 菌将单个菌落转移到200毫升锥形烧瓶中, 其中含有20毫升的 LB 辅以适当的抗生素 (即60和 #956; pET-28a-EFSAM) 的卡那霉素。在一夜之间 (即16小时) 在37和 #176 生长这种液体发酵剂; C. 190 rpm 的恒定晃动. </li>
	<li> 在步骤2.2 的同一天, 在4升锥形烧瓶中, 为 15 N 标记蛋白表达 M9 培养基, 灭菌 1 l M9 缓冲盐 (即 42 mm Na 2 HPO 22 , 2 mm, 4 mm PO 8.6 , 7.4 毫米氯化钠, pH 4)。一旦冷却, 过滤 20% (w/v) d-葡萄糖的混合物, 1 米 CaCl 2 , 1 m 硫胺素, 1 M MgSO 4 , 1 毫克/毫升生物素和0.2 克/毫升 15 N NH 4 Cl 通过一个0.2 和 #956; M 无菌注射器过滤到 1 L 无菌 M9 盐溶液, 使这些成分的最终浓度是 0.2% (w/v) d-葡萄糖, 100 和 #956; m CaCl 2 , 50 和 #956; m 硫胺素, 1 毫米 MgSO 4 , 1 和 #956; g/毫升生物素和1毫克/毫升 15 N NH 4 Cl. </li>
	<li> 第二天, 菌将20毫升的隔夜液体发酵剂转化为50毫升的无菌锥管, 离心机在2400和 #215; g 为15分钟, 将单元格颗粒. </li>
	<li> 在迁 LB 培养基后, 在10毫升的 M9 极小介质中重产生的细胞团, 并将悬浮颗粒混合物转化为 M9 最低培养基的1升, 抗生素 (即60和 #956;
	<li> 在37和 #176 中长出含有细菌起动培养物的 M9 最小培养基的1升; C 和〜 190 rpm 恒定晃动, 直到光学密度在 600 nm (OD600) 达到 ~ 0.6-0.8. </li>
	<li> 当到达 specfified OD600 范围时, 添加200和 #956; M 异丙和 #946;-D-1-thiogalactopyranoside (IPTG) 以诱导蛋白质表达. </li>
	<li> 在 IPTG 后, 继续在室温下以 190 rpm 为16小时 (即过夜) 对蛋白质表达的细胞进行孵化. </li>
	<li> 第二天, 用离心法采集1万、#215; g、4和 #176; C 30 min. </li>
	<li> 醒酒磅, 并将细胞颗粒转移到50毫升锥形管中。将小球储存在-80 和 #176; C 直到提纯. </li>
</ol> 3。从 大肠杆菌 中纯化重组蛋白. 
 注意: 不同的重组蛋白需要独特的纯化程序。以下是6和 #215 的协议;他标记的 EFSAM 纯化从 pET-28a 结构表达的包涵体. 
<ol> <li> 手动质6米胍-hcl 中的冷冻细菌细胞颗粒, 20 毫米三盐酸 (pH 8) 和5毫米和 #946;-基使用机动10毫升转移吸管。在这个步骤中, 每5毫升的湿细胞颗粒中加入大约40毫升的胍-HCl. </li>
	<li> 在环境温度下进行90分钟的孵化, 在杂交烤箱中进行恒定旋转, 将混合物离心于 ~ 1.5万和 #215; g、8和 #176; C 为40分钟, 将不溶性细胞碎片 ( 即 #160; 颗粒) 从可溶性蛋白中分离混合物 (即上清). </li>
	<li> 添加750和 #181; 50% (v/v) Ni 2 + -三酸琼脂糖珠浆对澄清的裂解产物, 并在室温下孵育另90分钟, 在杂交烤箱中反转. </li>
	<li> 随后, 捕获6和 #215; 他的标签蛋白绑定到 Ni 2 + 通过收集在重力流蛋白纯化柱的琼脂糖珠。在移动到步骤3.5 之前, 允许裂解液完全流过该列. </li>
	<li> 将收集到的珠子洗涤三次, 10 毫升的6米尿素, 20 毫米的三盐酸 pH 8 和5毫米和 #946;-基。确保整个 10 ml 在随后的10毫升洗涤之前通过该列. </li>
	<li> 用6米尿素、20毫米三盐酸洗 pH 8、300 mm 咪唑和5毫米和 #946 等一系列2毫升馏分中的蛋白质进行分离, 基与九十年代的潜伏期之间的时间。确保整个 2 mL 在每个后续洗脱步骤之前经过该列. </li>
	<li> 在此阶段, 使用 Laemmli 47 的方法确认马斯亮蓝染色的十二烷基硫酸钠聚丙烯酰胺凝胶电泳 (SDS 页) 中的洗馏分中存在感兴趣的蛋白。通过与标准分子量标记带相比, 对蛋白质的大小、数量和纯度进行比较, 它们都小于和大于所期望的蛋白质的分子量. </li>
	<li> 将洗蛋白组分放入具有 3500 Da 分子量截渗的透析膜中, 并在 1 L 复用缓冲液中孵育 (20 毫米三, 300 毫米氯化钠, 1 毫米的, 5 毫米 CaCl 2 , pH 8) 在4和 #176; C 过夜, 而缓冲是由 magneti 搅拌c 搅拌器. </li>
	<li> 在 16 h 的复性时间后, 将每毫克蛋白质的凝血酶直接添加到透析袋中, 并在4和 #176 孵育; C 为额外的 ~ 24 h. </li>
	<li> 验证6和 #215 的范围; 他的标签由马斯亮-蓝色染色的〜15和 #956; 从透析袋中取出的蛋白等分电泳在变性聚丙烯酰胺凝胶 (SDS 页) 中的应用Laemmli 47 的方法。如果迁移中的 2 kDa 移位与6和 #215 的分子量相对应; 他的标签, 继续步骤 3.11;如果一小部分未消化的蛋白质仍然是可检测的马斯亮蓝染色, 添加〜 0.2 U 的凝血酶每毫克蛋白直接到透析袋和孵化4和 #176; C 为额外的〜 24 h. </li>
	<li> 使用尺寸排除或离子交换色谱法进一步纯化蛋白质。对于 EFSAM 的阴离子交换色谱, 从透析袋中去除蛋白质溶液, 用 1万 Da 分子量截止的超滤离心浓缩器浓缩〜10倍。随后, re-dilute 的解决方案〜20倍, 在一个无 NaCl 缓冲 (20 毫米三, 5 毫米 CaCl 2 , 1 毫米的双制式, pH 8). </li>
	<li> 平衡预阴离子交换柱, 在步骤3.11 中描述了10列的无 NaCl 缓冲液的容量。平衡使用缓冲区加载到口锁注射器不包含气泡, 通过推动解决方案通过该列的滴方式, 并避免注射器压力, 导致稳定的解决方案, 退出列。使用强阴离子交换器 (如交联琼脂糖与季铵功能基团). </li>
	如步骤3.12 所述, <li> 将蛋白溶液稀释到不含氯化钠的缓冲液 (步骤 3.11) 上. </li>
	<li> 洗蛋白质和 #160; 在梯度 [即 0-60% (v/v)] 的增加 nacl 缓冲 (20 毫米三, 1 米氯化钠, 5 毫米 CaCl 2 , 1 毫米的数码, pH 8) 使用双泵快蛋白液相色谱 (FPLC) 系统。设置 FPLC 系统收集〜 1-1. 5 毫升分数和监测蛋白洗脱剖面使用 UV 280 nm 吸收率和流量0.5 毫升/分钟. </li>
	<li> 使用 Laemmli 47 的方法识别马斯亮蓝染色的 SDS 页凝胶中含有感兴趣蛋白和蛋白质纯度的洗脱峰和分数. </li>
	<li> 显示和 #62 的池分数; 95% (即以马斯亮-蓝色染色凝胶中仅显示单个蛋白带的分数) 放入透析袋中, 并按步骤3.8 中所述的透析交换到实验性缓冲中. </li>
</ol> 4。通过透析将 glucose-5-MTS 化学附着在蛋白质上. 
<ol> <li> 在500和 #956 中溶解10毫克的化合物, 制备 n-(和 #946; d-基)-n-和 #39;-[2-methanethiosulfonyl) 乙基] 脲 (glucose-5-MTS) 的55毫米库存溶液; 100% (v/五) 亚砜的 l。储存未使用的 glucose-5-MTS 溶解在-20 和 #176 的亚砜; C. </li>
	<li> 透析1.5 毫升的60和 #956 的蛋白质样品进行修饰; M 蛋白为1升的修饰缓冲器, 由 20 mm 拖把、150 mm 氯化钠、5 mm CaCl 2 和 0.1 mm TCEP、pH 8.3 组成。使用透析膜的分子量截面积小于蛋白质的大小被修改 (例如, 使用 3500 da 截止为〜 17500 da EFSAM). </li>
	<li> 24 小时后在4和 #176; C, 将样品从透析袋中转移到离心管中。将溶解 glucose-5-MTS 加入到最后浓度为 2 mM. </li>
	<li> 在室温下在黑暗中孵育样品1小时。在 1 h 潜伏期, 混合的解决方案, 轻轻敲击管每10分钟. </li>
	<li> 随后, 在4和 #176 的透析中, 将蛋白质交换到含有 no 还原剂的最终实验缓冲液中, 如步骤4.2 或离心超滤法所述。对于超滤过程, 将1.5 毫升蛋白质样品浓缩至 #60; 0.5 毫升, 然后在同一个选矿厂用实验缓冲液稀释。重复这一浓缩-稀释步骤两次, 使总交换最小值为30和 #215; 30 和 #215; 30 = 2.7万倍。对于 EFSAM, 使用20毫米三, 150 毫米氯化钠, 5 毫米 CaCl 2 , pH 7.5 作为实验缓冲. </li>
	<li> 分别将步骤4.2 和4.5 中所述的透析或超滤交换样品制备为25毫米碳酸氢铵或25毫米醋酸铵。如果使用透析, 确保您至少交换三次, 以消除任何残留氯化钠和 CaCl 2 盐. </li>
	<li> 使用电喷雾电离质谱法确定感兴趣的蛋白质的准确质量 (即 #177; 1 Da) 48 , 49 。期望每个共价键葡萄糖加入胱氨酸硫醇通过 methanethiosulfonate 化学添加 281.3 da 到蛋白质质量 (即增加 360.4 da 为 glucose-5-MTS 和减去 79.1 da 为 CH 3 , 因此 2 离开组在共价键期间附件). </li>
</ol> 5。modif 的溶液核磁共振评价─效率和结构摄动. 
<ol> <li> 确保修饰蛋白质的浓度为和 #62; 100 和 #956; M 在葡萄糖附着和最后的缓冲交换之后。对于 EFSAM, 估计蛋白质浓度使用紫外线消光系数在 280 nm 1.54 (毫克毫升 - 1 ) cm 1 。
	<li> 补充蛋白质溶液与60和 #956; 44-二甲基 4-silapentane-1-磺酸 (DSS) 的匀和脉冲校准和 10% (v/v) D 2 O 为信号锁。用于高信噪比使用600和 #956; L 样品在频率匹配的5毫米核磁共振管, 插入到至少600兆赫光谱仪配备了三重共振 HCN 低温探头. </li>
	<li> 收集标准 1 H- 15 n HSQC 光谱作为先前详细的 50 , 51 在温度下, 1 h 和 15 N 扫描宽度, 瞬态和增量适用于特定样品的设置。对于 EFSAM 谱, 使用20和 #176; C, 256 1 H 瞬态, 64 15 n 维增量和 1 H 和 15 n 扫描宽度分别设置为8000和 1800 Hz. </li>
	<li> 在糖化蛋白谱获得后, 将糖 (数码化) 从1米的库存中添加到最终浓度为15毫米的核磁共振样品中。通过减少二硫化物介导的附着物, 使其从蛋白质中去除葡萄糖的基团. </li>
	<li> 获取第二个 1 H- 15 N HSQC 在这些减少/未修改的条件下, 提供了一个参考频谱, 以评估由葡萄糖附着引起的修改效率和结构扰动. </li>
	<li> 使用 NMRPipe 处理核磁共振数据, 如前文所述 52 。确保最小化处理包括数据转换、分阶段、溶剂抑制、傅里叶变换和光谱的初始显示. </li>
	<li> 使用卡拉 NEASY 插件 53 对修改的和降低的光谱中的酰胺峰值强度和化学位移值进行测量, 以评估修改效率。确保对胱氨酸酰胺在葡萄糖附着和还原谱中的峰值强度进行评估。如果胱氨酸酰胺不能在这两种光谱中可靠地定位, 那么就使用相邻胱氨酸的残留强度作为读数. </li>
	<li> 计算的效率作为酰胺的强度从胱氨酸改性光谱除以酰胺的强度从胱氨酸减少 (即电算处理) 频谱, 乘以 100: 
	<img alt="Equation 1" src="/files/ftp_upload/56302/56302eq1.jpg"/>, 其中 I M 是胱氨酸修饰谱中的酰胺强度, i R 是胱氨酸降低光谱中酰胺的强度。或者, 对多个酰胺峰值的平均效率进行评估: <img alt="Equation 2" src="/files/ftp_upload/56302/56302eq2.jpg"/>, 其中 效率 i 是为各自计算的单独确定的效率残留物、 i、 和 n 是计算中使用的残滓总数. </li>
	<li> 计算化学位移扰动 (CSP) 从在 15 n 和 1 H 维度中观察到的两个光谱之间的化学位移的差异, 对较大的 15 N 化学位移范围使用以下等式: <img alt="Equation 3" src="/files/ftp_upload/56302/56302eq3.jpg"/>, 其中 和 #916; H 是在质子维度和 和 #916 中的 ppm 变化; N 是氮维数的 ppm 变化. </li> </ol>

蛋白质糖基化是一种修饰的修饰, 糖通过与氨基酸侧链的连接, 以共价键的多肽为主。多达50% 的哺乳动物蛋白质是糖化54, 其中糖化蛋白可以有不同范围的影响, 改变生物分子结合亲和力, 影响蛋白质折叠, 改变渠道活动, 目标降解和细胞贩运的分子, 命名为少数 (在33中进行了审查)。糖基化在哺乳动物生理学中的重要作用是由数百种蛋白质进化而来的, 以构建哺乳?...

存储操作钙 (ca2 +) 条目 (SOCE) 是免疫细胞从细胞外空间进入胞的主要途径.t 淋巴细胞, t 细胞受体位于细胞膜 (PM) 结合抗原, 激活蛋白酪氨酸激酶 (在1,2,3中进行了审查。磷酸化级联导致磷脂酶γ (PLCγ) 的活化, 随后将膜醇 45--1,6-(PIP2) 的水解转化为甘油和肌醇 14, 5-trisphosphate (IP3).ip3是一个小的扩散信使, 它绑定到内质网 (er) 上的 ip3受体 (ip3R), 从而打开这个受体通道, 并允许 Ca2 +从 ER 流下来的浓度梯度。流明到胞 (在4中进行了审阅)。受体信号从 G 蛋白耦合和酪氨酸激酶受体在各种其他易激动和不可的细胞类型导致相同的生产 ip3和激活 ip3Rs。
由于 ER 的有限 Ca2 +存储容量, IP3介导的释放和胞浆 ca2 +的结果增加只是暂时的;但是, er 腔 Ca2 +的这一损耗深刻影响了基质相互作用 molecule-1 (STIM1), 一种主要在 er 膜上发现的 I 型跨膜 (TM) 蛋白, 5,6,7。STIM1 包含一个面向流明的 Ca2 +传感域由一个 EF 手对和无菌α-主题 (EFSAM) 组成。三由单 TM 域与 EFSAM 分离的胞内定向盘绕线圈域 (在8中进行了评审)。当 ER 腔 Ca2 +耗尽时, EFSAM 经历了一个不稳定耦合的齐聚, 7,9 , 这将导致 TM 和盘绕线圈域的结构重10。这些结构的变化最终导致 STIM1 在 ER pm 路口的陷印11,12,13,14通过与 pm phosphoinositides 15的交互, 16和 Orai1 子单元17,18。Orai1 蛋白质是组装成 Ca2 +通道19、20、21、22的 PM 子单元。STIM1-Orai1 交互在 ER PM 连接促进开放的 ca2 +释放激活的 ca2 + (裂纹) 通道构象, 使 ca2 +的移动到胞从高浓度的细胞外空间。在免疫细胞中, 通过裂纹通道的持续胞浆钙离子 2 +的升高, 诱发了 ca 的2 +-钙调素/磷酸依赖性磷酸的核因子的活化 T 细胞, 随后进入细胞核和开始转录调控基因促进 T 细胞激活1,3。裂纹通道激活的过程由 STIM1 23,24通过激动剂诱发 ER 腔 ca2 +耗尽和结果持续的胞浆 ca2 +提升统称为 SOCE 25。SOCE 在 T 细胞中的重要作用是显而易见的研究表明, STIM1 和 Orai1 可遗传突变会导致严重的联合免疫缺陷综合症3,19,26, 27. EFSAM 启动 SOCE 后, 传感 ER 腔 ca2 +损耗通过 ca 的损失2 +协调在规范 EF 手, 最终导致不稳定耦合 self-association 7, 28,29。
糖基化是通过 ER 和高尔基体中的各种生物合成步骤 (在30,32,33) 中对寡糖结构的共价键连接和处理, 也称为糖。在真核生物中有两种主要的糖基化类型: N-链接和O链接, 具体取决于特定的氨基酸和原子桥接连接。在N-糖基化, 糖附着在 Asn 的侧链酰胺上, 在大多数情况下, 当多肽链移动到流明34时, 在 ER 中发生起始步骤。n的第一步-糖基化是由葡萄糖 (Glc)、甘露糖 (人) 和N-乙酰 (GlcNAc) (即 Glc3人9GlcNAc2) 从 ER膜脂由 oligosaccharyltransferase 35,36。进一步的步骤, 如分裂或转移葡萄糖残留, 是催化在 ER 由特定的糖苷和转移。一些蛋白质, 离开 ER 和移动到高尔基可以进一步处理37。O-糖基化指的是添加糖, 通常对侧链羟基的 Ser 或的残留物, 这一修改完全发生在高尔基复合体33,34。有几个O-糖结构, 可以由N-乙酰, 藻, 半乳糖, 和唾液酸, 每个单糖添加顺序33。
虽然没有任何特定的序列被确定为许多类型的O-糖基化的先决条件, 但一个共同的共识序列已经与N链接的修改相关联: Asn x Ser/胱氨酸, 其中 x 可以是任何氨基酸除了 Pro 33。STIM1 EFSAM 包含其中的两个共识N-糖基化的网站: Asn131-Trp132-Thr133 和 Asn171-Thr172-Thr173。事实上, 以前的研究表明, EFSAM 可以是N-糖化在哺乳动物细胞在 Asn131 和 Asn171 38,39,40,41。然而, 以前的研究的后果, N-糖基化对 SOCE 已不, 建议抑制, 强化或没有效果, 这修饰修改 SOCE 激活38,= "xref" > 39,40,41。因此, 对 EFSAM N-糖基化的基础生物物理、生物化学和结构后果的研究对于理解这种修改的调节作用至关重要。由于在这些体外实验中对高水平的均质蛋白的要求, 采用了一种以现场选择的方法将葡萄糖基共价附着在 EFSAM 上。有趣的是, Asn131 和 Asn171 糖基化导致了在 EFSAM 核心内聚集的结构变化, 并增强了促进 STIM1-mediated SOCE 42的生物物理特性。
糖组对胱氨酸硫的化学附着已被一项开创性工作所证实, 这一研究首次证明了这种无酶方法的效用, 以了解糖基化对蛋白质功能的 site-specific 作用43,44. 最近和关于 STIM1, Asn131 和 Asn171 残留物被变异了对胱氨酸和葡萄糖-5-(methanethiosulfonate) [葡萄糖 5-(MTS)] 被用共价键连接葡萄糖到自由的硫42。在这里, 我们描述了这种方法, 不仅使用诱变, 以纳入现场特定的胱氨酸残留物的修改, 但也应用解决方案核磁共振 (NMR) 光谱学, 以快速评估的修改效率和结构由于糖基化而引起的扰动。值得注意的是, 这种通用的方法很容易适应于研究任何 recombinantly 产生的蛋白质的O或N-糖基化的影响。

<table><tbody><tr><td>Phusion DNA Polymerase</td><td>Thermo Fisher Scientific</td><td>F530S</td><td>Use in step 1.3.</td></tr><tr><td>Generuler 1kb DNA Ladder</td><td>Thermo Fisher Scientific</td><td>FERSM1163</td><td>Use in step 1.6.</td></tr><tr><td>DpnI Restriction Enzyme</td><td>New England Biolabs, Inc.</td><td>R0176</td><td>Use in step 1.8.</td></tr><tr><td>Presto Mini Plasmid Kit</td><td>GeneAid, Inc.</td><td>PDH300</td><td>Use in step 1.16.</td></tr><tr><td>BL21 DE3 codon (+) E. coli</td><td>Agilent Technologies, Inc.</td><td>230280</td><td>Use in step 2.1.</td></tr><tr><td>DH5a E. coli</td><td>Invitrogen, Inc.</td><td>18265017</td><td>Use in step 1.9.</td></tr><tr><td>0.22 mm Syringe Filter</td><td>Millipore, Inc.</td><td>SLGV033RS</td><td>Use in step 2.3.</td></tr><tr><td>HisPur Ni&lt;sup&gt;2+&lt;/sup&gt;-NTA Agarose Resin</td><td>Thermo Fisher Scientific</td><td>88221</td><td>Use in step 3.3.</td></tr><tr><td>3,500 Da MWCO Dialysis Tubing</td><td>BioDesign, Inc.</td><td>D306</td><td>Use in step 3.8, 3.16, 4.2, 4.5 and 4.6.</td></tr><tr><td>Bovine Thrombin</td><td>BioPharm Laboratories, Inc.</td><td>SKU91-055</td><td>Use in step 3.9.</td></tr><tr><td>5 mL HiTrap Q FF Anion Exchange Column</td><td>GE Healthcare, Inc.</td><td>17-5156-01</td><td>Use in step 3.11.</td></tr><tr><td>Glucose-5-MTS</td><td>Toronto Research Chemicals, Inc.</td><td>G441000</td><td>Use in step 4.1.</td></tr><tr><td>Vivaspin 20 Ultrafiltration Centrifugal Concentrators</td><td>Sartorius, Inc.</td><td>VS2001</td><td>Use in step 3.11, 4.2, 4.5 and 4.6.</td></tr><tr><td>PageRuler Unstained Broad Protein Ladder</td><td>Thermo Fisher Scientific</td><td>26630</td><td>Use in step 3.7, 3.10 and 3.15</td></tr><tr><td>HiTrap Q FF Anion Exchange Column</td><td>GE Healthcare, Inc.</td><td>17-5053-01</td><td>Use in step 3.12.</td></tr><tr><td>AKTA Pure Fast Protein Liquid Chromatrography System</td><td>GE Healthcare, Inc.</td><td>29018224</td><td>Use in step 3.14.</td></tr><tr><td>600 MHz Varian Inova NMR Spectrometer</td><td>Agilent Technologies, Inc.</td><td></td><td>Use in step 5.2 and 5.5.</td></tr></tbody></table>

targeting cysteine thiols for in vitro site-specific glycosylation of recombinant proteins

基质相互作用 molecule-1 (STIM1) 是一种 I 型跨膜蛋白, 位于内质网 (ER) 和细胞膜 (PM)。ER 驻留 STIM1 调节 PM Orai1 通道的活动, 该过程称为存储操作钙 (ca2 +), 它是主要的 ca2 +信号处理程序, 它可驱动免疫应答。STIM1 经历修饰N-糖基化在两个腔 Asn 网站内的 Ca2 +传感领域的分子。然而, 直到最近, 由于无法轻易获得高水平的均质性蛋白质, 糖化 STIM1 的生物化学、生物物理和结构生物学效应都没有得到很好的理解. 在这里, 我们描述了一个体外化学方法的实现, 它将葡萄糖基附加到特定的蛋白质部位, 以了解N-糖基化对蛋白质结构和机制的潜在影响。使用溶液核磁共振波谱法, 我们评估的效率的修改, 以及结构的后果, 葡萄糖附件与单一样本。这种方法可以很容易地适应研究在自然界中发现的无数糖化蛋白。

这一方法的第一步要求将候选糖基化残留物诱变为胱氨酸残留物, 可以使用 glucose-5-MTS 进行修改. EFSAM 没有内生胱氨酸残留物, 因此在诱变.然而, 本地胱氨酸残留物必须在执行所描述的化学物质之前突变为不可残留物。为了最小地影响本机结构, 我们建议对感兴趣的蛋白质进行全球序列对准, 并确定在内源胱氨酸位置最常发现的其他残留物。胱氨酸突变对其他生物体自然发生...

Watch this Scientific Journal Video about Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins at JoVE.com

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

靶向半胱氨酸硫用于体外重组蛋白的特异糖基化

糖化蛋白的生物化学和结构分析需要相对较大数量的均质样品。在这里, 我们提出了一种有效的化学方法的 site-specific 糖基化的重组蛋白纯化细菌的靶向活性胱氨酸硫。

Stromal interaction molecule-1 (STIM1) is a type-I transmembrane protein located on the endoplasmic reticulum (ER) and plasma membranes (PM). ER-resident ...

targeting-cysteine-thiols-for-vitro-site-specific-glycosylation

Research

JoVE Journal

Immunology and Infection

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

6.5K 次观看.  University of Western Ontario. 糖化蛋白的生物化学和结构分析需要相对较大数量的均质样品。在这里, 我们提出了一种有效的化学方法的 site-specific 糖基化的重组蛋白纯化细菌的靶向活性胱氨酸硫。

视频: Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry

The chemical linking or bioconjugation of proteins to fluorescent dyes, drugs, polymers and other proteins has a broad range of applications, such as the development of antibody drug conjugates (ADCs) and nanomedicine, fluorescent microscopy and systems chemistry. For many of these applications, specificity of the bioconjugation method used is of prime concern. The Michael addition of maleimides with cysteine(s) on the target proteins is highly selective and proceeds rapidly under mild conditions, making it one of the most popular methods for protein bioconjugation.
We demonstrate here the modification of the only surface-accessible cysteine residue on yeast cytochrome c with a ruthenium(II) bisterpyridine maleimide. The protein bioconjugation is verified by gel electrophoresis and purified by aqueous-based fast protein liquid chromatography in 27% yield of isolated protein material. Structural characterization with MALDI-TOF MS and UV-Vis is then used to verify that the bioconjugation is successful. The protocol shown here is easily applicable to other cysteine - maleimide coupling of proteins to other proteins, dyes, drugs or polymers.

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry

This protocol details the important steps required for the bioconjugation of a cysteine containing protein to a maleimide, including reagent purification, reaction conditions, bioconjugate purification and bioconjugate characterization.

蛋白质生物缀合物的合成<em&gt;通过</em&gt;半胱氨酸马来酰亚胺化学

The chemical linking or bioconjugation of proteins to fluorescent dyes, drugs, polymers and other proteins has a broad range of applications, such as the ...

科研

化学

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Glycoproteins on the surface of cells play critical roles in cellular function, including signalling, adhesion and transport. On leukocytes, several of these glycoproteins possess immunoglobulin (Ig) folds and are central to immune recognition and regulation. Here, we present a platform for the design, expression and biophysical characterization of the extracellular domain of human B cell receptor CD22. We propose that these approaches are broadly applicable to the characterization of mammalian glycoprotein ectodomains containing Ig domains. Two suspension human embryonic kidney (HEK) cell lines, HEK293F and HEK293S, are used to express glycoproteins harbouring complex and high-mannose glycans, respectively. These recombinant glycoproteins with different glycoforms allow investigating the effect of glycan size and composition on ligand binding. We discuss protocols for studying the kinetics and thermodynamics of glycoprotein binding to biologically relevant ligands and therapeutic antibody candidates. Recombinant glycoproteins produced in HEK293S cells are amenable to crystallization due to glycan homogeneity, reduced flexibility and susceptibility to endoglycosidase H treatment. We present methods for soaking glycoprotein crystals with heavy atoms and small molecules for phase determination and analysis of ligand binding, respectively. The experimental protocols discussed here hold promise for the characterization of mammalian glycoproteins to give insight into their function and investigate the mechanism of action of therapeutics.

We present approaches for the biophysical and structural characterization of glycoproteins with the immunoglobulin fold by biolayer interferometry, isothermal titration calorimetry, and X-ray crystallography.

用 X 射线晶体学和生物物理技术表征免疫球蛋白折叠的糖蛋白

Glycoproteins on the surface of cells play critical roles in cellular function, including signalling, adhesion and transport. On leukocytes, several of ...

生物化学

Analysis of the Solvent Accessibility of Cysteine Residues on Maize rayado fino virus Virus-like Particles Produced in Nicotiana benthamiana Plants and Cross-linking of Peptides to VLPs

Mimicking and exploiting virus properties and physicochemical and physical characteristics holds promise to provide solutions to some of the world's most pressing challenges. The sheer range and types of viruses coupled with their intriguing properties potentially give endless opportunities for applications in virus-based technologies. Viruses have the ability to self- assemble into particles with discrete shape and size, specificity of symmetry, polyvalence, and stable properties under a wide range of temperature and pH conditions. Not surprisingly, with such a remarkable range of properties, viruses are proposed for use in biomaterials 9, vaccines 14, 15, electronic materials, chemical tools, and molecular electronic containers4, 5, 10, 11, 16, 18, 12.
In order to utilize viruses in nanotechnology, they must be modified from their natural forms to impart new functions. This challenging process can be performed through several mechanisms including genetic modification of the viral genome and chemically attaching foreign or desired molecules to the virus particle reactive groups 8. The ability to modify a virus primarily depends upon the physiochemical and physical properties of the virus. In addition, the genetic or physiochemical modifications need to be performed without adversely affecting the virus native structure and virus function. Maize rayado fino virus (MRFV) coat proteins self-assemble in Escherichia coli producing stable and empty VLPs that are stabilized by protein-protein interactions and that can be used in virus-based technologies applications 8. VLPs produced in tobacco plants were examined as a scaffold on which a variety of peptides can be covalently displayed 13. Here, we describe the steps to 1) determine which of the solvent-accessible cysteines in a virus capsid are available for modification, and 2) bioconjugate peptides to the modified capsids. By using native or mutationally-inserted amino acid residues and standard coupling technologies, a wide variety of materials have been displayed on the surface of plant viruses such as, Brome mosaic virus 3, Carnation mottle virus 12, Cowpea chlorotic mottle virus 6, Tobacco mosaic virus 17, Turnip yellow mosaic virus 1, and MRFV 13.

Analysis of the Solvent Accessibility of Cysteine Residues on Maize rayado fino virus Virus-like Particles Produced in Nicotiana benthamiana Plants and Cross-linking of Peptides to VLPs

A method to analyze the solvent accessibility of the thiol group of cysteine residues of Maize rayado fino virus (MRFV)-virus-like particles (VLPs) followed by a peptide cross-linking reaction is described. The method takes advantage of the availability of several chemical groups on the surface of the VLPs that can be targets for specific reactions.

半胱氨酸残基的溶剂可及性分析<em&gt;玉米rayado菲诺病毒</em病毒样颗粒<em&gt;烟草</em植物和交联的肽类病毒颗粒

Mimicking  and exploiting virus properties and physicochemical and physical  characteristics holds promise to provide solutions to some of  the world's ...

免疫与感染

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Maleimide-bearing bifunctional probes have been employed for decades for the site-selective modification of thiols in biomolecules, especially antibodies. Yet maleimide-based conjugates display limited stability in vivo because the succinimidyl thioether linkage can undergo a retro-Michael reaction. This, of course, can lead to the release of the radioactive payload or its exchange with thiol-bearing biomolecules in circulation. Both of these processes can produce elevated activity concentrations in healthy organs as well as decreased activity concentrations in target tissues, resulting in reduced imaging contrast and lower therapeutic ratios. In 2018, we reported the creation of a modular, stable, and easily accessible phenyloxadiazolyl methyl sulfone reagent &#8212; dubbed &#8216;PODS&#8217; &#8212; as a platform for thiol-based bioconjugations. We have clearly demonstrated that PODS-based site-selective bioconjugations reproducibly and robustly create homogenous, well-defined, highly immunoreactive, and highly stable radioimmunoconjugates. Furthermore, preclinical experiments in murine models of colorectal cancer have shown that these site-selectively labeled radioimmunoconjugates exhibit far superior in vivo performance compared to radiolabeled antibodies synthesized via maleimide-based conjugations. In this protocol, we will describe the four-step synthesis of PODS, the creation of a bifunctional PODS-bearing variant of the ubiquitous chelator DOTA (PODS-DOTA), and the conjugation of PODS-DOTA to the HER2-targeting antibody trastuzumab.

In this protocol, we will describe the synthesis of PODS, a phenyoxadiazolyl methyl sulfone-based reagent for the site-selective attachment of cargos to the thiols of biomolecules, particularly antibodies. In addition, we will describe the synthesis and characterization of a PODS-bearing bifunctional chelator and its conjugation to a model antibody.

硫醇反应试剂的合成与生物共轭作用--用于原位选择性修饰免疫共轭的生成

Maleimide-bearing bifunctional probes have been employed for decades for the site-selective modification of thiols in biomolecules, especially antibodies. ...

Preparation of Site-Specific Cytotoxic Protein Conjugates via Maleimide-thiol Chemistry and Sortase A-Mediated Ligation

Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their surface. This feature enables development of highly selective therapeutics, the protein bioconjugates, composed of targeting proteins (antibodies or receptor ligands) connected to highly cytotoxic drugs by a specific linker. Due to very high affinity and selectivity of targeting proteins the bioconjugates recognize marker proteins on the cancer cells surface and utilize receptor-mediated endocytosis to reach the cell interior. Intracellular vesicular transport system ultimately delivers the bioconjugates to the lysosomes, where proteolysis separates free cytotoxic drugs from the proteinaceous core of the bioconjugates, triggering drug-dependent cancer cell death. Currently, there are several protein bioconjugates approved for cancer treatment and large number is under development or clinical trials.
One of the main challenges in the generation of the bioconjugates is a site-specific attachment of the cytotoxic drug to the targeting protein. Recent years have brought a tremendous progress in the development of chemical and enzymatic strategies for protein modification with cytotoxic drugs. Here we present the detailed protocols for the site-specific incorporation of cytotoxic warheads into targeting proteins using a chemical method employing maleimide-thiol chemistry and an enzymatic approach that relies on sortase A-mediated ligation. We use engineered variant of fibroblast growth factor 2 and fragment crystallizable region of human immunoglobulin G as an exemplary targeting proteins and monomethyl auristatin E and methotrexate as model cytotoxic drugs. All the described strategies allow for highly efficient generation of biologically active cytotoxic conjugates of defined molecular architecture with potential for selective treatment of diverse cancers.

Here we provide detailed protocols for a site-specific labeling of proteins with cytotoxic drugs using maleimide-thiol reaction and sortase A-mediated ligation.

Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as ...

Resin-Assisted Capture Coupled with Isobaric Tandem Mass Tag Labeling for Multiplexed Quantification of Protein Thiol Oxidation

Reversible oxidative modifications on protein thiols have recently emerged as important mediators of cellular function. Herein we describe the detailed procedure of a quantitative redox proteomics method that utilizes resin-assisted capture (RAC) in combination with tandem mass tag (TMT) isobaric labeling and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to allow multiplexed stochiometric quantification of oxidized protein thiols at the proteome level. The site-specific quantitative information on oxidized cysteine residues provides additional insight into the functional impacts of such modifications. 
The workflow is adaptable across many sample types, including cultured cells (e.g., mammalian, prokaryotic) and whole tissues (e.g., heart, lung, muscle), which are initially lysed/homogenized and with free thiols being alkylated to prevent artificial oxidation. The oxidized protein thiols are then reduced and captured by a thiol-affinity resin, which streamlines and simplifies the workflow steps by allowing the proceeding digestion, labeling, and washing procedures to be performed without additional transfer of proteins/peptides. Finally, the labeled peptides are eluted and analyzed by LC-MS/MS to reveal comprehensive stoichiometric changes related to thiol oxidation across the entire proteome. This method greatly improves the understanding of the role of redox-dependent regulation under physiological and pathophysiological states related to protein thiol oxidation.

Protein thiol oxidation has significant implications under normal physiological and pathophysiological conditions. We describe the details of a quantitative redox proteomics method, which utilizes resin-assisted capture, isobaric labeling, and mass spectrometry, enabling site-specific identification and quantification of reversibly oxidized cysteine residues of proteins.

树脂辅助捕获与同量异位串联质量标签标记相结合，用于蛋白质硫醇氧化的多重定量

Reversible oxidative modifications on protein thiols have recently emerged as important mediators of cellular function. Herein we describe the detailed ...

Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins

Protein glycosylation is one of the most common and complex post-translational modifications. Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins. A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F). However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins. In addition, free glycans have also been described in mammalian cells, bacteria, yeast, plants, and fish. In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins. In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1&#8722;3:1) and a longer incubation time (48&#8722;72 h). The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.

This study presents a method for glycomics analysis of glycoproteins by a combination of pronase E digestion, permethylation, and mass spectrometry analysis. This method is capable of analyzing all types of N-linked glycans, including bacterial N-glycans.

Protein glycosylation is one of the most common and complex post-translational modifications. Many techniques have been developed to characterize the ...

Examining the Conformational Dynamics of Membrane Proteins in situ with Site-directed Fluorescence Labeling

Two electrode voltage clamp electrophysiology (TEVC) is a powerful tool to investigate the mechanism of ion transport1 for a wide variety of membrane proteins including ion channels2, ion pumps3, and transporters4. Recent developments have combined site-specific fluorophore labeling alongside TEVC to 
concurrently examine the conformational dynamics at specific residues and function of these proteins on the surface of single cells.
We will describe a method to study the conformational dynamics of membrane proteins by simultaneously monitoring fluorescence and current changes using voltage-clamp fluorometry. This approach can be used to examine the molecular motion of membrane proteins site-specifically following cysteine replacement and site-directed fluorophore labeling5,6. Furthermore, this method provides an approach to determine distance constraints between specific residues7,8. 
This is achieved by selectively attaching donor and acceptor fluorophores to two mutated cysteine residues of interest.
In brief, these experiments are performed following functional expression of the desired protein on the surface of Xenopus leavis oocytes. The large surface area of these oocytes enables facile functional measurements and a robust fluorescence signal5. It is also possible to readily change the extracellular conditions such as pH, ligand or cations/anions, which can provide further information on the mechanism of membrane proteins4. Finally, recent developments 
have also enabled the manipulation of select internal ions following co-expression with a second protein9.
Our protocol is described in multiple parts. First, cysteine scanning mutagenesis proceeded by fluorophore labeling is completed at residues located at the interface of the transmembrane and extracellular domains. Subsequent experiments are designed to identify residues which demonstrate large changes in fluorescence intensity (&lt;5%)3 upon a conformational change of the protein. Second, these changes in fluorescence intensity are compared to the kinetic parameters of 
the membrane protein in order to correlate the conformational dynamics to the function of the protein10. This enables a rigorous biophysical analysis of the molecular motion of the target protein. Lastly, two residues of the holoenzyme can be labeled with a donor and acceptor fluorophore in order to determine distance constraints using donor photodestruction methods. It is also possible to monitor the relative movement of protein subunits following labeling with a donor and acceptor fluorophore.

Examining the Conformational Dynamics of Membrane Proteins in situ with Site-directed Fluorescence Labeling

We will describe a method which measures the kinetics of ion transport of membrane proteins alongside site-specific analysis of conformational changes using fluorescence on single cells. This technique is adaptable to ion channels, transporters and ion pumps and can be utilized to determine distance constraints between protein subunits.

研究膜蛋白的构象动力学原位网站的荧光标记

Two electrode voltage clamp electrophysiology (TEVC) is a powerful tool to investigate the mechanism of ion transport1 for a wide variety of membrane ...

生物学

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Genetic code expansion is a powerful tool to introduce unnatural amino acids (UAAs) into proteins to modify their characteristics, to study or create new protein functions or to have access to protein conjugates. Stop codon suppression, in particular amber codon suppression, has emerged as the most popular method to genetically introduce UAAs at defined positions. This methodology is herein applied to the preparation of a carrier protein containing an UAA harboring a bioorthogonal functional group. This reactive handle can next be used to specifically and efficiently graft a synthetic oligosaccharide hapten to provide a homogeneous glycoconjugate vaccine. The protocol is limited to the synthesis of glycoconjugates in a 1:1 carbohydrate hapten/carrier protein ratio but amenable to numerous pairs of biorthogonal functional groups. Glycococonjugate vaccine homogeneity is an important criterion to ensure complete physico-chemical characterization, thereby, satisfying more and more demanding drug regulatory agency recommendations, a criterion which is unmet by classical conjugation strategies. Moreover, this protocol makes it possible to finely tune the structure of the actual conjugate vaccine, giving rise to tools to address structure-immunogenicity relationships.

Genetic code expansion is applied for the introduction of an unnatural amino acid bearing a biorthogonal functional group on a carrier protein at a defined site. The biorthogonal function is further used for the site-selective coupling of a carbohydrate antigen to provide a homogeneous glycoconjugate vaccine.

联合非自然氨基酸合并和点击化学为疫苗目的生产的同质糖共酶

Genetic code expansion is a powerful tool to introduce unnatural amino acids (UAAs) into proteins to modify their characteristics, to study or create new ...

生物工程

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Recombinant monoclonal antibodies bind specific molecular targets and, subsequently, induce an immune response or inhibit the binding of other ligands. However, monoclonal antibody functionality and half-life may be reduced by the type and distribution of host-specific glycosylation. Attempts to produce superior antibodies have inspired the development of genetically modified producer cells that synthesize glyco-optimized antibodies. Glycoengineering typically requires the generation of a stable knockout or knockin cell line using methods such as clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9. Monoclonal antibodies produced by engineered cells are then characterized using mass spectrometric methods to determine if the desired glycoprofile has been obtained. This strategy is time-consuming, technically challenging, and requires specialists. Therefore, an alternative strategy that utilizes streamlined protocols for genetic glycoengineering and glycan detection may assist endeavors toward optimal antibodies. In this proof-of-concept study, an IgG-producing Chinese hamster ovary cell served as an ideal host to optimize glycoengineering. Short interfering RNA targeting the Fut8 gene was delivered to Chinese hamster ovary cells, and the resulting changes in FUT8 protein expression were quantified. The results indicate that knockdown by this method was efficient, leading to a ~60% reduction in FUT8. Complementary analysis of the antibody glycoprofile was performed using a rapid yet highly sensitive technique: capillary gel electrophoresis and laser-induced fluorescence detection. All knockdown experiments showed an increase in afucosylated glycans; however, the greatest shift achieved in this study was ~20%. This protocol simplifies glycoengineering efforts by harnessing in silico design tools, commercially synthesized gene targeting reagents, and rapid quantification assays that do not require extensive prior experience. As such, the time efficiencies offered by this protocol may assist investigations into new gene targets.

The glycosylation pattern of an antibody determines its clinical performance, thus industrial and academic efforts to control glycosylation persist. Since typical glycoengineering campaigns are time- and labor-intensive, the generation of a rapid protocol to characterize the impact of glycosylation genes using transient silencing would prove useful.

仓鼠卵巢细胞的快速抗体糖工程

Recombinant monoclonal antibodies bind specific molecular targets and, subsequently, induce an immune response or inhibit the binding of other ligands. ...

靶向半胱氨酸硫用于体外重组蛋白的特异糖基化

摘要

探索更多视频

此视频中的章节

蛋白质生物缀合物的合成